Showing 1 of 1 PublicationsPulmonary Toxicities from Checkpoint Immunotherapy for MalignancyPossick JD. Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. Clinics In Chest Medicine 2017, 38: 223-232. PMID: 28477635, DOI: 10.1016/j.ccm.2016.12.012.ChaptersCitationsMeSH Keywords and ConceptsMeSH KeywordsHumansImmunotherapyLung Diseases, InterstitialNeoplasmsConceptsCheckpoint immunotherapyPulmonary toxicitySignificant pulmonary toxicitySpectrum of malignanciesAdverse eventsClinical vigilancePD-1Clinical featuresOncologic therapyCTLA-4ImmunotherapyMalignancyTherapyToxicityOutcomesIrAEsPatientsAgentsIncidenceImmuneDownload Full List
Pulmonary Toxicities from Checkpoint Immunotherapy for MalignancyPossick JD. Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. Clinics In Chest Medicine 2017, 38: 223-232. PMID: 28477635, DOI: 10.1016/j.ccm.2016.12.012.ChaptersCitationsMeSH Keywords and ConceptsMeSH KeywordsHumansImmunotherapyLung Diseases, InterstitialNeoplasmsConceptsCheckpoint immunotherapyPulmonary toxicitySignificant pulmonary toxicitySpectrum of malignanciesAdverse eventsClinical vigilancePD-1Clinical featuresOncologic therapyCTLA-4ImmunotherapyMalignancyTherapyToxicityOutcomesIrAEsPatientsAgentsIncidenceImmune